Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Long-Term Deferred Tax: 2022-2023

Historic Long-Term Deferred Tax for InMed Pharmaceuticals (INM) over the last 2 years, with Jun 2023 value amounting to $21.2 million.

  • InMed Pharmaceuticals' Long-Term Deferred Tax rose 13.26% to $21.2 million in Q2 2023 from the same period last year, while for Jun 2023 it was $21.2 million, marking a year-over-year increase of 13.26%. This contributed to the annual value of $21.2 million for FY2023, which is 13.26% up from last year.
  • As of FY2023, InMed Pharmaceuticals' Long-Term Deferred Tax stood at $21.2 million, which was up 13.26% from $18.8 million recorded in FY2022.
  • In the past 5 years, InMed Pharmaceuticals' Long-Term Deferred Tax ranged from a high of $21.2 million in FY2023 and a low of $18.8 million during FY2022.
  • Its 2-year average for Long-Term Deferred Tax is $20.0 million, with a median of $20.0 million in 2022.
  • Data for InMed Pharmaceuticals' Long-Term Deferred Tax shows a peak YoY rose of 13.26% (in 2023) over the last 5 years.
  • Over the past 2 years, InMed Pharmaceuticals' Long-Term Deferred Tax (Yearly) stood at $18.8 million in 2022, then grew by 13.26% to $21.2 million in 2023.